Lung cancer is the one of the most common types of cancer doctors diagnose each year in the U.S. The most common kind of lung cancer is non-small-cell lung cancer (NSCLC). It makes up around 84% ...

Once non-small-cell lung cancer (NSCLC) spreads far and wide, treating it is kind of a balancing act. A cure isn't likely, but you can slow it down. So you aim to relieve your symptoms and improve ...

“Optune Lua is an innovative and urgently needed new approach for treating metastatic non-small cell lung cancer,” said Joachim Aerts, M.D., a LUNAR investigator and Professor of Pulmonary ...

2024 — Researchers have demonstrated that patients with metastatic non-squamous non-small cell lung cancer (NSCLC) harboring specific mutations in the STK11 and/or KEAP1 tumor suppressor genes ...

French drugmaker Sanofi has halted the development of its antibody-drug conjugate (ADC) tusamitamab ravtansine after the drug failed a phase 3 trial in non-small cell lung cancer (NSCLC).

A new study published in The Annals of Thoracic Surgery suggests that Medicaid expansion under the Affordable Care Act has ...

Fig 1. Proposed randomized phase III trial schema. ECOG PS, Eastern Cooperative Oncology Group performance status; NSCLC, non–small cell lung cancer; ORR, overall response rate; OS, overall survival; ...

The study, published April 11 in The Annals of Thoracic Surgery, analyzed data from adults ages 40 to 64 with resected stage 1 or 2 non-small cell lung cancer between 2010 and 2016. Researchers ...

The COCOON trial regimen halved grade 2 or higher dermatologic side effects compared to standard care in EGFR-mutant non-small cell lung cancer patients. A two-fold reduction in severe dermatologic ...

First-line Rybrevant plus Lazcluze significantly extended overall survival versus Tagrisso in mutated, advanced or metastatic non-small cell lung cancer. Among patients with mutated, locally advanced ...

"Optune Lua is an innovative and urgently needed new approach for treating metastatic non-small cell lung cancer," said Joachim Aerts, M.D., a LUNAR investigator and Professor of Pulmonary ...